Brian D Bradbury

Summary

Affiliation: Amgen Inc
Country: USA

Publications

  1. ncbi Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina
    Brian D Bradbury
    Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts, USA
    Cancer 103:1114-21. 2005
  2. ncbi Confounding and control of confounding in nonexperimental studies of medications in patients with CKD
    Brian D Bradbury
    Center for Observational Research, Amgen Inc, Thousand Oaks, CA 91320, USA
    Adv Chronic Kidney Dis 19:19-26. 2012
  3. ncbi Departure from multiplicative interaction for catechol-O-methyltransferase genotype and active/passive exposure to tobacco smoke among women with breast cancer
    Brian D Bradbury
    Department of Epidemiology, Boston University School of Public Health, 715 Albany St, T3E, Boston, MA 02118, USA
    J Carcinog 5:3. 2006
  4. ncbi Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients
    Brian D Bradbury
    Department of Biostatistics and Epidemiology, Amgen Inc, Thousand Oaks, CA 91320, USA
    Nephrol Dial Transplant 24:919-25. 2009
  5. ncbi Conversion of vascular access type among incident hemodialysis patients: description and association with mortality
    Brian D Bradbury
    Department of Biostatistics and Epidemiology, Amgen Inc, Thousand Oaks, CA 91320, USA
    Am J Kidney Dis 53:804-14. 2009
  6. ncbi Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL
    Brian D Bradbury
    Department of Biostatistics and Epidemiology, Amgen, Inc, Thousand Oaks, California 41984, USA
    Clin J Am Soc Nephrol 4:630-7. 2009
  7. ncbi Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in nonexperimental research: strengths and limitations
    Brian D Bradbury
    Department of Biostatistics and Epidemiology, Amgen Inc, Thousands Oaks, CA 91320, USA
    Am J Kidney Dis 54:554-60. 2009
  8. ncbi Exploring relative mortality and epoetin alfa dose among hemodialysis patients
    Brian D Bradbury
    Department of Biostatistics and Epidemiology, Amgen Inc, Thousand Oaks, CA 91320, USA
    Am J Kidney Dis 51:62-70. 2008
  9. ncbi Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)
    Brian D Bradbury
    Department of Global Epidemiology, Amgen, Inc, Thousand Oaks, California 91320, USA
    Clin J Am Soc Nephrol 2:89-99. 2007
  10. ncbi Test-retest reliability of colorectal testing questions on the Massachusetts Behavioral Risk Factor Surveillance System (BRFSS)
    Brian D Bradbury
    Boston University School of Medicine, Boston Collaborative Drug Surveillance Program, 11 Muzzey Street, Lexington, MA 02421, USA
    Prev Med 41:303-11. 2005

Detail Information

Publications19

  1. ncbi Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina
    Brian D Bradbury
    Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts, USA
    Cancer 103:1114-21. 2005
    ..The effect persisted with increasing cumulative dose and length of use. CONCLUSIONS: The treatment of breast carcinoma with tamoxifen was found to reduce a woman's risk of acute MI or angina during the 5 years of recommended therapy...
  2. ncbi Confounding and control of confounding in nonexperimental studies of medications in patients with CKD
    Brian D Bradbury
    Center for Observational Research, Amgen Inc, Thousand Oaks, CA 91320, USA
    Adv Chronic Kidney Dis 19:19-26. 2012
    ..The availability and expanded use of large health care databases have ensured greater precision and have now placed the focus on validity. Addressing the major threats to validity, such as confounding, should be a first-order concern...
  3. ncbi Departure from multiplicative interaction for catechol-O-methyltransferase genotype and active/passive exposure to tobacco smoke among women with breast cancer
    Brian D Bradbury
    Department of Epidemiology, Boston University School of Public Health, 715 Albany St, T3E, Boston, MA 02118, USA
    J Carcinog 5:3. 2006
    ..8, 10). CONCLUSION : With greater control over potential misclassification errors and a large case-only population, we found evidence to support an interaction between COMT genotype and tobacco smoke exposure in breast cancer etiology...
  4. ncbi Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients
    Brian D Bradbury
    Department of Biostatistics and Epidemiology, Amgen Inc, Thousand Oaks, CA 91320, USA
    Nephrol Dial Transplant 24:919-25. 2009
    ..We sought to investigate the association between C-reactive protein (CRP) levels and average per-administration epoetin alfa (EPO) dose over 3 months following a CRP measurement...
  5. ncbi Conversion of vascular access type among incident hemodialysis patients: description and association with mortality
    Brian D Bradbury
    Department of Biostatistics and Epidemiology, Amgen Inc, Thousand Oaks, CA 91320, USA
    Am J Kidney Dis 53:804-14. 2009
    ..Limited data exist describing vascular access conversions during the first year on dialysis therapy or the effect of converting to and from a catheter on subsequent mortality risk...
  6. ncbi Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL
    Brian D Bradbury
    Department of Biostatistics and Epidemiology, Amgen, Inc, Thousand Oaks, California 41984, USA
    Clin J Am Soc Nephrol 4:630-7. 2009
    ....
  7. ncbi Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in nonexperimental research: strengths and limitations
    Brian D Bradbury
    Department of Biostatistics and Epidemiology, Amgen Inc, Thousands Oaks, CA 91320, USA
    Am J Kidney Dis 54:554-60. 2009
    ..Here, we describe sources of bias in nonexperimental studies of ESA therapy in hemodialysis patients and critically appraise analytical methods that may help minimize bias in such studies...
  8. ncbi Exploring relative mortality and epoetin alfa dose among hemodialysis patients
    Brian D Bradbury
    Department of Biostatistics and Epidemiology, Amgen Inc, Thousand Oaks, CA 91320, USA
    Am J Kidney Dis 51:62-70. 2008
    ..Two recent publications reported that greater epoetin alfa (EPO) doses were associated with increased mortality rates. We assessed whether confounding-by-indication might account for these results...
  9. ncbi Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)
    Brian D Bradbury
    Department of Global Epidemiology, Amgen, Inc, Thousand Oaks, California 91320, USA
    Clin J Am Soc Nephrol 2:89-99. 2007
    ..Inadequate predialysis nephrology care was strongly associated with mortality during this period, highlighting the potential benefits of contact with a nephrologist at least 1 mo before HD initiation...
  10. ncbi Test-retest reliability of colorectal testing questions on the Massachusetts Behavioral Risk Factor Surveillance System (BRFSS)
    Brian D Bradbury
    Boston University School of Medicine, Boston Collaborative Drug Surveillance Program, 11 Muzzey Street, Lexington, MA 02421, USA
    Prev Med 41:303-11. 2005
    ....
  11. ncbi Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL
    Brian D Bradbury
    Department of Biostatistics and Epidemiology, Amgen, Inc, Thousand Oaks, CA 91320, USA
    Pharmacoepidemiol Drug Saf 18:932-40. 2009
    ....
  12. ncbi Relationship between epoetin alfa dose and mortality: findings from a marginal structural model
    Ouhong Wang
    Department of Global Biostatistics and Epidemiology, Amgen Inc, Thousand Oaks, California 91320, USA
    Clin J Am Soc Nephrol 5:182-8. 2010
    ..The relationship between EPO dose and 1-year mortality, adjusting for the effects of time-dependent CBI, was examined using a marginal structural model...
  13. ncbi Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients
    Ryan D Kilpatrick
    Department of Biostatistics and Epidemiology, Amgen Inc, One Amgen Center Drive, MS 24 2 A, Thousand Oaks, CA 91320, USA
    Clin J Am Soc Nephrol 3:1077-83. 2008
    ..Among hemodialysis patients, achieved hemoglobin is associated with Epoetin alfa dose and erythropoietin responsiveness. A prospective erythropoietin responsiveness measure was developed and its association with mortality evaluated...
  14. ncbi Hospitalization risks related to vascular access type among incident US hemodialysis patients
    Leslie J Ng
    Department of Biostatistics and Epidemiology, Amgen Inc, Thousand Oaks, CA, USA
    Nephrol Dial Transplant 26:3659-66. 2011
    ..We examined hospitalization burden related to vascular access (VA) type among incident patients who received some predialysis care...
  15. ncbi Exploring large weight deletion and the ability to balance confounders when using inverse probability of treatment weighting in the presence of rare treatment decisions
    Ryan D Kilpatrick
    Center for Observational Research, Amgen Inc, Thousand Oaks, CA 91320, USA
    Pharmacoepidemiol Drug Saf 22:111-21. 2013
    ..We sought to explore these assumptions empirically in the context of epoetin-alfa (EPO) dosing and mortality...
  16. ncbi Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009
    Deborah Regidor
    Department of Biostatistics and Epidemiology, Amgen, Inc, Thousand Oaks, CA 91320, USA
    Nephrol Dial Transplant 26:1583-91. 2011
    ..The extent to which these events influenced ESA dosing and Hb levels in patients with chronic kidney disease not on dialysis (CKD-NOD) is not known...
  17. ncbi Obesity and the risk of prostate cancer (United States)
    Brian D Bradbury
    Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, 11 Muzzey Street, Lexington, MA 02421, USA
    Cancer Causes Control 16:637-41. 2005
    ..This study provides modest support for a protective association between obesity and the risk of incident prostate cancer...
  18. ncbi The effect of altitude on dosing and response to erythropoietin in ESRD
    M Alan Brookhart
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA
    J Am Soc Nephrol 19:1389-95. 2008
    ..Furthermore, resistance to EPO decreased with elevation. Our results suggest that ESRD patients living at high altitude either increase endogenous EPO production or respond better to endogenous and exogenous EPO...
  19. ncbi Hemoglobin level variability: associations with mortality
    David T Gilbertson
    Chronic Disease Research Group, Minneapolis Medical Research Foundation, 914 South 8th Street, Suite S 206, Minneapolis, MN 55404, USA
    Clin J Am Soc Nephrol 3:133-8. 2008
    ..4%; intermediate-intermediate (I-I), 6.0%; high-high (H-H), 2.3%; low-intermediate (L-I), 18.3%; intermediate-high (I-H), 31.7%, and low-high (L-H), 40.2%...